Absci Corp: insider trades · United States · SEC (Form 4)

About Absci Corp

Absci Corp (ticker: ABSI) is a U.S.-listed company on the Nasdaq exchange in the United States. For French-speaking investors, it is best viewed as a small-cap healthcare/biotech name sitting at the intersection of generative AI and drug discovery. The company describes itself as a clinical-stage biopharmaceutical company focused on designing differentiated antibody therapeutics through an AI-native platform paired with scalable wet-lab capabilities. Its headquarters are in Vancouver, Washington, with AI research labs in New York City and Serbia, plus an innovation center in Zug, Switzerland. ([investors.absci.com](https://investors.absci.com/?utm_source=openai)) Absci’s corporate history dates back to August 2011, when it was founded as an Oregon LLC. It later became a Delaware LLC in 2016 and was reorganized into a Delaware corporation in 2020. That path is consistent with a venture-backed deep-tech company evolving into a public biotech platform business. Today, Absci’s core value proposition is its “AI Drug Creation” platform, which combines generative models, antibody engineering, multiparametric optimization, and experimental validation to accelerate biologics discovery and improve candidate quality. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1672688/000162828022023604/absci-sx3.htm?utm_source=openai)) Operationally, the company is pursuing two complementary strategies. First, it is advancing its own internal pipeline of proprietary assets. The most visible programs are ABS-101, an anti-TL1A antibody being developed for inflammatory bowel disease, and ABS-201, an anti-prolactin receptor antibody aimed at androgenetic alopecia, with potential expansion into endometriosis. Second, Absci works with pharmaceutical, biotech, technology, and academic partners to validate and monetize its platform capabilities. This dual model — internal pipeline plus external partnerships — is central to its investment case and competitive positioning. ([investors.absci.com](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-fourth-quarter-and-full-1?utm_source=openai)) In competitive terms, Absci remains an early-stage company with limited operating scale and no established commercial product revenue. Its differentiation lies in the promise to shorten biologics discovery timelines, lower costs, and increase the probability of success. That said, the investment case remains highly execution-dependent, with clinical readouts, partnership wins, and capital discipline all likely to drive sentiment. Recent milestones have been meaningful: in 2025, Absci reported first dosing in Phase 1 studies for ABS-101 and Phase 1/2a studies for ABS-201; in 2026, it expanded ABS-201 into endometriosis and continued to highlight progress across its pipeline. A collaboration with Oracle and AMD to accelerate AI-driven drug discovery also underscored the company’s technology ambitions. ([investors.absci.com](https://investors.absci.com/news-releases/news-release-details/absci-announces-first-participants-dosed-phase-1-clinical-trial/?utm_source=openai))